AU2002362383B2 - Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies - Google Patents
Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies Download PDFInfo
- Publication number
- AU2002362383B2 AU2002362383B2 AU2002362383A AU2002362383A AU2002362383B2 AU 2002362383 B2 AU2002362383 B2 AU 2002362383B2 AU 2002362383 A AU2002362383 A AU 2002362383A AU 2002362383 A AU2002362383 A AU 2002362383A AU 2002362383 B2 AU2002362383 B2 AU 2002362383B2
- Authority
- AU
- Australia
- Prior art keywords
- lysine
- sequence seq
- serine
- acetylated
- phosphorylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 128
- 230000001363 autoimmune Effects 0.000 title claims description 19
- 230000007170 pathology Effects 0.000 title claims description 19
- 230000004481 post-translational protein modification Effects 0.000 title claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 title description 55
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 141
- 239000004472 Lysine Substances 0.000 claims description 135
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 135
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 127
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 125
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 241001529936 Murinae Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 210000000987 immune system Anatomy 0.000 claims description 6
- 230000021736 acetylation Effects 0.000 claims description 5
- 238000006640 acetylation reaction Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 210000001324 spliceosome Anatomy 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 108010061100 Nucleoproteins Proteins 0.000 claims description 2
- 102000011931 Nucleoproteins Human genes 0.000 claims description 2
- 108010047956 Nucleosomes Proteins 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 210000001623 nucleosome Anatomy 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 description 70
- 241000699670 Mus sp. Species 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 108010061749 spliceosomal peptide P140 Proteins 0.000 description 10
- 238000001819 mass spectrum Methods 0.000 description 8
- 101100447171 Arabidopsis thaliana FRO2 gene Proteins 0.000 description 7
- 101001108927 Rattus norvegicus Nuclear pore complex protein Nup155 Proteins 0.000 description 7
- 102100031876 SRC kinase signaling inhibitor 1 Human genes 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 206010025135 lupus erythematosus Diseases 0.000 description 5
- LSLBZWAEEUGETG-GGVFYUGVSA-N p140 peptide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)C(=O)[C@H](CONCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NP(O)(O)=O)C1=CN=CN1 LSLBZWAEEUGETG-GGVFYUGVSA-N 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 108091005601 modified peptides Proteins 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 230000003172 anti-dna Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0112041A FR2829768B1 (fr) | 2001-09-18 | 2001-09-18 | Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes |
| FR01/12041 | 2001-09-18 | ||
| PCT/FR2002/003186 WO2003025014A2 (fr) | 2001-09-18 | 2002-09-18 | Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002362383A1 AU2002362383A1 (en) | 2003-06-05 |
| AU2002362383B2 true AU2002362383B2 (en) | 2008-10-09 |
Family
ID=8867384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002362383A Expired AU2002362383B2 (en) | 2001-09-18 | 2002-09-18 | Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7872098B1 (enExample) |
| EP (2) | EP2338908A1 (enExample) |
| JP (1) | JP4160505B2 (enExample) |
| AU (1) | AU2002362383B2 (enExample) |
| CA (1) | CA2460704A1 (enExample) |
| FR (1) | FR2829768B1 (enExample) |
| WO (1) | WO2003025014A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030186849A1 (en) * | 2001-09-06 | 2003-10-02 | Zimmer Robert H. | Modified peptides and their use for the treatment of autoimmune diseases |
| FR2931360B1 (fr) * | 2008-05-20 | 2012-05-18 | Centre Nat Rech Scient | Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs |
| IN2014MN01376A (enExample) | 2011-12-13 | 2015-04-17 | Centre Nat Rech Scient | |
| US10213482B2 (en) | 2014-12-12 | 2019-02-26 | Immupharma France Sa | Methods of treating chronic inflammatory diseases |
| US20210308211A1 (en) * | 2020-03-29 | 2021-10-07 | Immupharma France Sa | Method of treating viral infections |
| CN119241701A (zh) * | 2024-09-27 | 2025-01-03 | 珠海丽禾医疗诊断产品有限公司 | U1-70k结合蛋白、制备方法和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030186849A1 (en) * | 2001-09-06 | 2003-10-02 | Zimmer Robert H. | Modified peptides and their use for the treatment of autoimmune diseases |
-
2001
- 2001-09-18 FR FR0112041A patent/FR2829768B1/fr not_active Expired - Lifetime
-
2002
- 2002-09-18 EP EP10183969A patent/EP2338908A1/fr not_active Withdrawn
- 2002-09-18 EP EP02798771A patent/EP1427755A2/fr not_active Ceased
- 2002-09-18 US US10/489,967 patent/US7872098B1/en active Active
- 2002-09-18 WO PCT/FR2002/003186 patent/WO2003025014A2/fr not_active Ceased
- 2002-09-18 JP JP2003528859A patent/JP4160505B2/ja not_active Expired - Lifetime
- 2002-09-18 AU AU2002362383A patent/AU2002362383B2/en not_active Expired
- 2002-09-18 CA CA002460704A patent/CA2460704A1/fr not_active Abandoned
-
2010
- 2010-10-27 US US12/913,232 patent/US8475800B2/en not_active Expired - Lifetime
-
2013
- 2013-06-11 US US13/914,997 patent/US20140004136A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8475800B2 (en) | 2013-07-02 |
| FR2829768B1 (fr) | 2003-12-12 |
| EP2338908A1 (fr) | 2011-06-29 |
| JP4160505B2 (ja) | 2008-10-01 |
| US20120149652A1 (en) | 2012-06-14 |
| FR2829768A1 (fr) | 2003-03-21 |
| JP2005510469A (ja) | 2005-04-21 |
| US7872098B1 (en) | 2011-01-18 |
| WO2003025014A2 (fr) | 2003-03-27 |
| US20140004136A1 (en) | 2014-01-02 |
| WO2003025014A3 (fr) | 2004-02-19 |
| EP1427755A2 (fr) | 2004-06-16 |
| CA2460704A1 (fr) | 2003-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mouthon et al. | Mechanisms of action of intravenous immune globulin in immune‐mediated diseases | |
| US6210669B1 (en) | Methods and compositions for immunomodulation | |
| US20110177093A1 (en) | Use of bcma as an immunoregulatory agent | |
| US20140004136A1 (en) | Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies | |
| EP1004312A1 (en) | Method for treating multiple sclerosis | |
| AU721898B2 (en) | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein | |
| JP2018508522A (ja) | 抗炎症性ポリペプチド | |
| US5753625A (en) | Treatment for inhibiting the progression of autoimmune disease | |
| WO2016145086A1 (en) | Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use | |
| JP4108601B2 (ja) | 修飾ペプチドおよび自己免疫疾患を治療するためのその使用 | |
| Briand et al. | Emerging peptide therapeutics for inflammatory autoimmune diseases | |
| NZ336745A (en) | A method of treating an animal with an autoimmune condition such as rheumatoid arthritis and relapsing polychrondritis | |
| EP1082967B1 (en) | Prevention and treatment of autoimmune demyelinating diseases by Fas-antagonists | |
| JP2005510469A5 (enExample) | ||
| CN107106672B (zh) | 用于预防和治疗免疫介导性疾病的针对胞壁酰肽的单克隆抗体 | |
| JP2002521387A (ja) | 共重合体１および関連する共重合体ならびにペプチドによる自己免疫疾患の治療 | |
| US20150104472A1 (en) | C1q PEPTIDES AND USES THEREOF | |
| EA019358B1 (ru) | Аллель- и изотип-специфическая интервенция в ассоциированные с аутоиммунными заболеваниями молекулы класса ii мнс при помощи пептидов | |
| Sitaraman | Myasthenia gravis: Role of cytokines in disease and design of therapy | |
| Kamiguchi et al. | Non‐Major Histocompatibility Complex Antigen Class I‐Regulatory Molecule for Cytotoxicity by Natural Killer Cells | |
| JPWO1999062554A1 (ja) | 自己免疫性脱髄性疾患予防・治療剤 | |
| HK1028554A (en) | Method for treating multiple sclerosis | |
| HK1227413A1 (en) | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions | |
| AU3685899A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |